4.

MAP2K4与ER共同表达模型与乳腺癌临床参数之间的关系

Correlation between the clinicopathologic characteristics and MAP2K4 and ER co-expression patterns in breast cancer

Variables	ER	MAP2K4 & ER (%)
		n	Positive	Negative	P
Age (year)
>45	Positive	36	14(38.9%)	22(61.1%)
	Negative	15	8 (53.3%)	7 (46.7%)	0.343
≤45	Positive	26	11 (42.3%)	15 (57.7%)
	Negative	19	9 (47.4%)	10 (52.6%)	0.736
Tumor scale
≤2	Positive	10	2 (20.0%)	8 (80.0%)	0.104
	Negative	11	6 (54.5%)	5 (45.5%)
> 2, ≤3	Positive	22	9 (40.9%)	13 (59.1%)	0.316
	Negative	10	6 (60.0%)	4 (40.0%)
> 3, ≤5	Positive	22	12 (54.5%)	10 (45.5%)	0.357
	Negative	6	2 (33.3%)	4 (66.7%)
> 5, ≤7	Positive	5	2 (40.0%)	3 (60.0%)	0.49
	Negative	5	1 (20.0%)	4 (80.0%)
> 7	Positive	3	0	3	0.025
	Negative	2	2	0
Clinical stage
Ⅰ-Ⅱ	Positive	56	20 (35.7%)	36 (64.3%)	0.182
	Negative	34	17 (50.0%)	17 (50.0%)
Ⅲ-Ⅵ	Positive	6	5 (83.3%)	1 (16.7%)	1.000
	Negative	6	5 (83.3%)	1 (16.7%)
Lymph node metastasis
0	Positive	27	10 (37.0%)	17 (63.0%)	0.211
	Negative	10	6 (60.0%)	4 (40.0%)
1-3	Positive	14	6 (42.9%)	8 (57.1%)	0.716
	Negative	12	6 (50.0%)	6 (50.0%)
4-9	Positive	14	8 (57.1%)	6 (42.9%)	0.265
	Negative	9	3 (33.3%)	6 (66.7%)
≥10	Positive	5	0	5	0.008
	Negative	2	2	0
Lymph node invasion
Yes	Positive	25	8 (32.0%)	17 (68.0%)	0.07
	Negative	9	6 (66.7%)	3 (33.3%)
No	Positive	36	17 (47.2%)	19 (52.8%)	0.672
	Negative	24	10 (41.7%)	14 (58.3%)